Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders: caution-review of indications and outcome / 白血病·淋巴瘤

ABSTRACT

The clinical features were reviewed for polycythemia vera, primary throbocythemia and primary myelofibrosis. Their indications and rational for allogeneic hematopoietic stem sell transplantation (allo-HCT) were recommended. The outcome after allo-HCT was described briefly. The significance of JAK2 mutation, especially V617F, detected for the minimal residual disease was introduced.